Moderna and Merck report successful trial for AI-designed cancer therapy

Moderna and Merck announced that their custom-tailored cancer vaccine, when paired with an established immunotherapy drug, significantly reduced the likelihood of melanoma returning in patients following surgery. In a major late-stage clinical trial, the combined regimen proved more effective at keeping patients disease-free than using the standard immunotherapy alone.

The experimental therapy uses software to scan genetic data from a patient's tumor, identifying unique mutations that are most likely to spur an immune response. Researchers then use those findings to produce a personalized mRNA shot engineered specifically for that individual. This result represents the first time a custom mRNA cancer treatment has successfully cleared a Phase 3 trial.

For everyday healthcare, this development brings tailor-made cancer treatments closer to reality. Instead of relying solely on broad-spectrum therapies, doctors may eventually be able to offer high-risk skin cancer patients a vaccine designed to train their own immune system to track down and destroy any lingering cancer cells.

However, key practical questions remain about how fast pharmaceutical manufacturers can produce these custom therapies for large numbers of patients and what the cost will mean for insurers and hospitals. It also remains to be seen whether this AI-assisted mRNA strategy will achieve similar success against other tough-to-treat solid tumors.